Results 201 to 210 of about 6,458 (228)
Some of the next articles are maybe not open access.
Reversible Thrombocytopenia Associated with Eptifibatide
The Annals of Pharmacotherapy, 2002OBJECTIVE: To report a patient who experienced severe, reversible thrombocytopenia after receiving eptifibatide for acute coronary syndrome. CASE SUMMARY: A 61-year-old white man with a past medical history of coronary artery disease, peripheral vascular disease, insulin-dependent diabetes, hypertension, and dyslipidemia was treated with eptifibatide ...
Rebecca F Edwards, Monty Yoder
openaire +3 more sources
Eptifibatide-induced thrombocytopenia and thrombosis
Journal of Thrombosis and Thrombolysis, 2006Glycoprotein (GP) IIb/IIIa inhibitors have been shown to reduce morbidity and mortality in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). With their widespread use, there is a growing body of literature describing adverse outcomes, including severe thrombocytopenia.
Mike Militello +4 more
openaire +2 more sources
Eptifibatide-induced profound thrombocytopaenia: a rare complication
BMJ Case Reports, 2021Drug-induced immune thrombocytopaenia (DITP) is a type of thrombocytopaenia caused by medications. It is one of the common causes of unexplained thrombocytopaenia. It is caused by the formation of autoantibodies against a particular drug and is commonly observed with medications like heparin and beta-lactam antibiotics.
Pranav Mahajan +3 more
openaire +3 more sources
Eptifibatide-Associated Acute, Profound Thrombocytopenia
Annals of Pharmacotherapy, 2005OBJECTIVE: To describe 3 cases of eptifibatide-associated acute, profound thrombocytopenia. CASE SUMMARIES: A 40-year-old black female received eptifibatide 180-μg/kg double bolus followed by a continuous infusion of 2 μg/kg/min for percutaneous coronary intervention (PCI).
James C. Coons +3 more
openaire +2 more sources
Evaluación económica de eptifibatide
Revista Española de Cardiología, 2001Introduccion y objetivos El objetivo de este estudio es realizar una evaluacion economica para Espana del ensayo PURSUIT, un estudio multicentrico y aleatorio sobre el tratamiento de la angina inestable o el infarto sin onda Q con eptifibatide frente a placebo, asi como medir el coste de cada ano de vida ganado en los pacientes tratados con dicho ...
Francisco Antón Botella +1 more
openaire +2 more sources
American Heart Journal, 1999
The primary cause of acute coronary syndromes is the development of a thrombus, a pathologic manifestation of platelet aggregation that occurs as part of the normal process of hemostasis. The discovery that the final common step in platelet aggregation, through the binding of fibrinogen to the activated platelet integrin glycoprotein (GP) IIb/IIIa, has
openaire +2 more sources
The primary cause of acute coronary syndromes is the development of a thrombus, a pathologic manifestation of platelet aggregation that occurs as part of the normal process of hemostasis. The discovery that the final common step in platelet aggregation, through the binding of fibrinogen to the activated platelet integrin glycoprotein (GP) IIb/IIIa, has
openaire +2 more sources
Acute Profound Thrombocytopenia Associated with Eptifibatide Therapy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003An 80‐year‐old woman and a 79‐year‐old man underwent urgent percutaneous coronary intervention and received adjunctive eptifibatide. Platelet counts in both patients fell to below 20 times 103/mm3 within 4 hours of eptifibatide administration. Reports in the medical literature reinforce the importance of recognizing that eptifibatide can cause acute ...
Cynthia A. Jackevicius +7 more
openaire +3 more sources
Eptifibatide-Induced Thrombocytopenia and Subsequent Thrombosis
Journal of Pharmacy Technology, 2012Objective: To report a case of thrombocytopenia and thrombosis associated with the administration of eptifibatide. Case Summary: We describe the case of a 63-year-old male who developed thrombocytopenia and thrombosis associated with eptifibatide administration. Eptifibatide (2 μg/kg/min, following a 180-μg/kg bolus) was administered on hospital day 5,
Hani Kador +3 more
openaire +2 more sources
Severe thrombocytopenia possibly related to readministration of eptifibatide
Catheterization and Cardiovascular Interventions, 2001AbstractThrombocytopenia following eptifibatide therapy is a rare event, and acute severe thrombocytopenia following readministration has not been reported. We describe a case of acute severe thrombocytopenia following reexposure to eptifibatide during percutaneous coronary intervention.
Susan Hurden +4 more
openaire +3 more sources
Intracoronary delivery of eptifibatide with the ClearWay® RX infusion catheter
Catheterization and Cardiovascular Interventions, 2011AbstractAcute coronary syndromes are caused by plaque rupture and the formation of an occlusive thrombus. Intracoronary (IC) bolus administration of eptifibatide may result in higher levels of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor occupancy (RO) in the local coronary bed, disaggregate thrombus in the epicardial artery, and ...
C. Michael Gibson, Albert J. Deibele
openaire +3 more sources